Literature DB >> 30105806

Internal quality control status for BNP and NT-proBNP in China from 2014 to 2017.

Huizhen Sun1,2, Wei Wang1, Haijian Zhao1, Chuanbao Zhang1, Falin He1, Kun Zhong1, Shuai Yuan1, Zhiguo Wang1.   

Abstract

BACKGROUND: This study aimed to investigate and analyze the status of internal quality control (IQC) for BNP and NT-proBNP from 2014 to 2017, so as to have an integral understanding of quality performance of measurement in clinical laboratories in China.
METHODS: The 4-year IQC information for BNP and NT-proBNP of participant laboratories were collected through EQA reporting system. Percentages of laboratories meeting different quality requirements (pass rates) for current coefficient of variations (CVs) were calculated afterwards. Further analysis for current CVs and pass rates among different years and measurement systems were conducted. Finally, we analyzed and summarized IQC practice and its changes in 4 years.
RESULTS: The current CVs for BNP and NT-proBNP have decreased significantly from 2014 to 2017, and pass rates both presented significant increasing trends. NT-proBNP had higher pass rates than BNP regardless of 1/3TEa or 1/4TEa specification was used. The main measurement systems for two analytes were different. For NT-proBNP, current CVs of Roche has decreased significantly among 4 years and were significantly lower than Radiometer and BioMérieux in 2015. Current CVs of Abbott also had decreasing tendency for BNP. Analysis of IQC practice indicated that control rules and IQC frequency had made great progress in 4 years.
CONCLUSION: The imprecision performance of measurement of BNP and NT-proBNP has improved with decreasing of current CVs and increasing of pass rates in 4 years. However, it still needs continual improvement. Clinical laboratories in China should take active actions to promote performance of BNP and NT-proBNP measurement.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  BNP; NT-proBNP; imprecision; internal quality control; quality specification

Mesh:

Substances:

Year:  2018        PMID: 30105806      PMCID: PMC6430442          DOI: 10.1002/jcla.22643

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  26 in total

1.  Imprecision Investigation and Analysis of Routine Chemistry in China.

Authors:  Yang Fei; Wei Wang; Falin He; Kun Zhong; Zhiguo Wang
Journal:  J Clin Lab Anal       Date:  2015-09-30       Impact factor: 2.352

2.  Status of internal quality control for thyroid hormones immunoassays from 2011 to 2016 in China.

Authors:  Shishi Zhang; Wei Wang; Haijian Zhao; Falin He; Kun Zhong; Shuai Yuan; Zhiguo Wang
Journal:  J Clin Lab Anal       Date:  2017-02-15       Impact factor: 2.352

3.  Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

4.  Internal quality control status for BNP and NT-proBNP in China from 2014 to 2017.

Authors:  Huizhen Sun; Wei Wang; Haijian Zhao; Chuanbao Zhang; Falin He; Kun Zhong; Shuai Yuan; Zhiguo Wang
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

Review 5.  IQC Laboratory management strategy for medical biology.

Authors:  Estelle Bugni; Richard Cohen; Cécile Mazellier
Journal:  Ann Biol Clin (Paris)       Date:  2017-12-01       Impact factor: 0.459

Review 6.  State of the art of immunoassay methods for B-type natriuretic peptides: An update.

Authors:  Aldo Clerico; Maria Franzini; Silvia Masotti; Concetta Prontera; Claudio Passino
Journal:  Crit Rev Clin Lab Sci       Date:  2014-12-30       Impact factor: 6.250

7.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

8.  The utility of biomarker risk prediction score in patients with chronic heart failure.

Authors:  Alexander E Berezin; Alexander A Kremzer; Yulia V Martovitskaya; Tatyana A Berezina; Tatyana A Samura
Journal:  Clin Hypertens       Date:  2016-03-11

9.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more
  1 in total

1.  Internal quality control status for BNP and NT-proBNP in China from 2014 to 2017.

Authors:  Huizhen Sun; Wei Wang; Haijian Zhao; Chuanbao Zhang; Falin He; Kun Zhong; Shuai Yuan; Zhiguo Wang
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.